Bleakley Financial Group LLC Has $6.02 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bleakley Financial Group LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 28.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,146 shares of the medical equipment provider's stock after buying an additional 2,713 shares during the period. Bleakley Financial Group LLC's holdings in Intuitive Surgical were worth $6,016,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Castleark Management LLC raised its holdings in shares of Intuitive Surgical by 3.4% during the 4th quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock valued at $47,221,000 after purchasing an additional 2,990 shares in the last quarter. Arlington Trust Co LLC raised its holdings in shares of Intuitive Surgical by 34.5% during the 1st quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock valued at $369,000 after purchasing an additional 191 shares in the last quarter. Aaron Wealth Advisors LLC raised its holdings in shares of Intuitive Surgical by 3.2% during the 1st quarter. Aaron Wealth Advisors LLC now owns 2,509 shares of the medical equipment provider's stock valued at $1,243,000 after purchasing an additional 78 shares in the last quarter. Ewing Morris & Co. Investment Partners Ltd. bought a new position in shares of Intuitive Surgical during the 4th quarter valued at $454,000. Finally, Whalerock Point Partners LLC bought a new position in shares of Intuitive Surgical during the 4th quarter valued at $209,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president directly owned 907 shares of the company's stock, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jami K. Nachtsheim sold 2,400 shares of the firm's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the transaction, the director directly owned 6,371 shares of the company's stock, valued at $3,312,920. The trade was a 27.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,998 shares of company stock valued at $2,611,577 over the last quarter. 0.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ISRG shares. Royal Bank Of Canada cut their price target on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Citigroup reiterated a "buy" rating and issued a $650.00 target price (up from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Evercore ISI raised their target price on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Truist Financial lowered their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Finally, Piper Sandler lowered their target price on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $592.59.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $512.06 on Monday. The company's fifty day moving average is $537.85 and its two-hundred day moving average is $536.67. The firm has a market capitalization of $183.53 billion, a price-to-earnings ratio of 75.08, a P/E/G ratio of 5.43 and a beta of 1.64. Intuitive Surgical, Inc. has a 52-week low of $413.82 and a 52-week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. During the same period last year, the firm earned $1.50 EPS. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.